Multidisciplinary Management of Lateral Skull Base Paragangliomas: A 20-Year Experience

 

 Buy Article Permissions and Reprints

Abstract

Objectives Paragangliomas of the lateral skull base are rare, largely benign, neuroendocrine tumors. Little evidence exists to support clinicians in the management of these tumors. The present study evaluates considerations in the multidisciplinary workup and management of paragangliomas affecting the lateral skull base.

Methods A STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist compliant retrospective review of adult patients with lateral skull base paragangliomas over 20 years (2002–2021) was performed. Patient and tumor data were collected from patient health care records.

Results Seventy patients were identified including 21 (30.0%) males and 49 (70.0%) females. The mean length of follow-up was 87.3 months (range: 12–239 months). Twenty-nine (41.4%) patients had Fisch A or B tumors. Overall, 57 patients (81.4%) were offered treatment upfront, with 13 patients (18.6%) initially undergoing active surveillance. Younger age and reduced American Society of Anesthesiologists (ASA) grade was significantly associated with a decision to offer treatment at presentation (both p = 0.03), while all patients with succinate dehydrogenase (SDH) mutations (n = 10) and tumor secretion (n = 4) were offered treatment. Patients with Fisch A/B tumors (p = 0.01), cranial neuropathies (p = 0.01), and smaller tumors (p = 0.01) were more likely to undergo surgical resection. At the time of the last follow-up, the proportion of patients with a cranial neuropathy was notably lower in the observation (3/12, 25.0%) and radiotherapy (1/6, 16.7%) groups.

Conclusions In our series, younger, fitter patients with SDH mutations, cranial neuropathies, or tumor secretion were more likely to be offered upfront treatment. There was a low incidence of new cranial neuropathy in the patients selected for observation during long-term follow-up.

Note

This work has been presented at the 2023 British Skull Base Society meeting.

Ethical Approval

Local institutional ethical approval was obtained.

Publication History

Received: 02 April 2023

Accepted: 17 August 2023

Accepted Manuscript online:
22 August 2023

Article published online:
25 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Galan SR, Kann PH. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrinol (Oxf) 2013; 78 (02) 165-175
  CrossrefPubMedGoogle Scholar
• 2 Valero C, Ganly I, Shah JP. Head and neck paragangliomas: 30-year experience. Head Neck 2020; 42 (09) 2486-2495
  CrossrefPubMedGoogle Scholar
• 3 Rana MU, Østhus AA, Heimdal K, Jebsen P, Revheim MR, Osnes TA. Head and neck paragangliomas in Norway, importance of genetics, updated diagnostic workup and treatment. Acta Otolaryngol 2021; 141 (03) 303-308
  CrossrefPubMedGoogle Scholar
• 4 Lenders JW, Duh QY, Eisenhofer G. et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99 (06) 1915-1942
  CrossrefPubMedGoogle Scholar
• 5 Jansen JC, van den Berg R, Kuiper A, van der Mey AG, Zwinderman AH, Cornelisse CJ. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 2000; 88 (12) 2811-2816
  CrossrefPubMedGoogle Scholar
• 6 Jansen TTG, Timmers HJLM, Marres HAM, Kunst HPM. Feasibility of a wait-and-scan period as initial management strategy for head and neck paraganglioma. Head Neck 2017; 39 (10) 2088-2094
  CrossrefPubMedGoogle Scholar
• 7 Harrison L, Corbridge R. Active surveillance management of head and neck paragangliomas: case series and review of the literature. J Laryngol Otol 2017; 131 (07) 580-584
  CrossrefPubMedGoogle Scholar
• 8 Neskey DM, Hatoum G, Modh R. et al. Outcomes after surgical resection of head and neck paragangliomas: a review of 61 patients. Skull Base 2011; 21 (03) 171-176
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Smith JD, Harvey RN, Darr OA. et al. Head and neck paragangliomas: a two-decade institutional experience and algorithm for management. Laryngoscope Investig Otolaryngol 2017; 2 (06) 380-389
  CrossrefPubMedGoogle Scholar
• 10 Osinga TE, Korpershoek E, de Krijger RR. et al. Catecholamine-synthesizing enzymes are expressed in parasympathetic head and neck paraganglioma tissue. Neuroendocrinology 2015; 101 (04) 289-295
  CrossrefPubMedGoogle Scholar
• 11 Burton BN, Hu JQ, Jafari A. et al. An updated assessment of morbidity and mortality following skull base surgical approaches. Clin Neurol Neurosurg 2018; 171: 109-115
  CrossrefPubMedGoogle Scholar
• 12 Cleere EF, Mizrachi A, Cohen MA, O'Neill JP. Editorial: advances in the diagnosis and treatment of skull base tumours. Front Oncol 2022; 12: 887595
  CrossrefPubMedGoogle Scholar
• 13 Lloyd S, Obholzer R, Tysome J. BSBS Consensus Group. British Skull Base Society Clinical Consensus Document on management of head and neck paragangliomas. Otolaryngol Head Neck Surg 2020; 163 (03) 400-409
  CrossrefPubMedGoogle Scholar
• 14 Jansen TTG, Timmers HJLM, Marres HAM, Kaanders JHAM, Kunst HPM. Results of a systematic literature review of treatment modalities for jugulotympanic paraganglioma, stratified per Fisch class. Clin Otolaryngol 2018; 43 (02) 652-661
  CrossrefPubMedGoogle Scholar
• 15 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335 (7624) 806-808
  CrossrefPubMedGoogle Scholar
• 16 Tamaki A, Nyirjesy S, Cabrera CI. et al. Treatment decision and estimation of growth of head and neck paragangliomas. Am J Otolaryngol 2022; 43 (02) 103357
  CrossrefPubMedGoogle Scholar
• 17 Moore MG, Netterville JL, Mendenhall WM, Isaacson B, Nussenbaum B. Head and neck paragangliomas: an update on evaluation and management. Otolaryngol Head Neck Surg 2016; 154 (04) 597-605
  CrossrefPubMedGoogle Scholar
• 18 Cleere EF, Martin-Grace J, Gendre A, Sherlock M, O'Neill JP. Contemporary management of paragangliomas of the head and neck. Laryngoscope Investig Otolaryngol 2021; 7 (01) 93-107
  CrossrefPubMedGoogle Scholar
• 19 Bacciu A, Ait Mimoune H, D'Orazio F, Vitullo F, Russo A, Sanna M. Management of facial nerve in surgical treatment of previously untreated Fisch class C tympanojugular paragangliomas: long-term results. J Neurol Surg B Skull Base 2014; 75 (01) 1-7
  PubMedGoogle Scholar
• 20 Hinerman RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM. Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck 2008; 30 (11) 1431-1438
  CrossrefPubMedGoogle Scholar
• 21 Dharnipragada R, Butterfield JT, Dhawan S, Adams ME, Venteicher AS. Modern management of complex tympanojugular paragangliomas: systematic review and meta-analysis. World Neurosurg 2022
  PubMedGoogle Scholar
• 22 Jansen TTG, Kaanders JHAM, Beute GN, Timmers HJLM, Marres HAM, Kunst HPM. Surgery, radiotherapy or a combined modality for jugulotympanic paraganglioma of Fisch class C and D. Clin Otolaryngol 2018; 43 (06) 1566-1572
  CrossrefPubMedGoogle Scholar
• 23 Erickson D, Kudva YC, Ebersold MJ. et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001; 86 (11) 5210-5216
  CrossrefPubMedGoogle Scholar
• 24 Yildiz E, Dahm V, Gstoettner W. et al. Long-term outcome and comparison of treatment modalities of temporal bone paragangliomas. Cancers (Basel) 2021; 13 (20) 5083
  CrossrefPubMedGoogle Scholar

• Supplementary Material